Regulatory guidelines from the Medicines and Healthcare products Regulatory Agency state that only people classified as clinically obese, with a Body Mass Index (BMI) of more than 30, or those who are overweight (BMI of 27-30) with at least one weight-related health condition such as high blood pressure or type 2 diabetes, will be eligible to receive the drug
Ongoing monitoring typically includes repeat HbA1c at 12 weeks post-initiation and every 3 to 6 months thereafter, along with periodic renal function checks
And last year, Eli Lilly acquired the biopharmaceutical company Versanis, which makes a drug that blocks receptors that regulate skeletal muscle and fat mass
Treatment should always be supervised by a qualified healthcare provider and integrated with comprehensive lipedema management including compression, lymphatic therapy, and provider-guided nutritional strategies
S., Garzon, S., Casarin, J., Franchi, M., & Ghezzi, F